Neuroimmunological Diseases

Herausgegeben:Kusunoki, Susumu

• Gebundenes Buch

Produktbeschreibung

This book offers a detailed review of the remarkable advances that have been made in research on the pathogenesis of a number of neuroimmunological diseases, as well as outlining novel treatments including the use of monoclonal antibodies. Written by renowned experts who have made major contributions in the field, such as identifying neuromyelitis optica as an immunopathological clinical condition, identifying the role of ganglioside and ganglioside-complex antibodies in Guillain-Barré syndrome, and developing a novel treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, the book summarizes recent advances in basic and clinical research. Neuroimmunological Diseases is a useful resource for not only researchers but also neurologists who are engaged in the management of neuroimmunological diseases.

Produktdetails

• Verlag: Springer / Springer Japan / Springer, Berlin
• Artikelnr. des Verlages: 978-4-431-55593-3
• 1st ed. 2016
• Seitenzahl: 300
• Erscheinungstermin: 6. Juli 2016
• Englisch
• Abmessung: 241mm x 160mm x 21mm
• Gewicht: 638g
• ISBN-13: 9784431555933
• ISBN-10: 4431555935
• Artikelnr.: 42961911

Autorenporträt

Susumu Kusunoki, Professor and Chairman, Department of Neurology, Kinki University School of Medicine

Inhaltsangabe

Part I. Basic Neuroimmunology.- 1. Cellular Immunity and multiple sclerosis: Current understanding.- 2. Glia and neuroimmunology.- 3. Animal model.- 4. Blood-brain barrier and blood-nerve barrier.- Part II. Clinical Neuroimmunology.- 5. Multiple Sclerosis: etiology and mechanism, with special reference to Asians.- 6. Multiple sclerosis: Diagnosis and treatment.- 7. Neuropsychological aspects of multiple sclerosis.- 8. Neuromyelitis optica: Diagnosis and treatment.- 9. Guillain-Barré syndrome: Epidemiology, diagnosis and treatment.- 10. Autoantibodies in Guillain-Barre syndrome.- 11. Fisher syndrome.- 12. POEMS syndrome.- 13. Treatment of myasthenia gravis after the 2014 Japanese clinical guideline.- 14. N-methyl-D-aspartate receptor antibody-associated autoimmune encephalitis.- 15. Hashimoto encephalopathy.- 16. Paraneoplastic neurological diseases.- 17. Antibodies to ganglionic acetylcholine receptor.- 18. Novel treatment.